Hurdles in Anticancer Drug Development from a Regulatory Perspective

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2012 Feb 22

PMID 22349015

Citations 8

Authors

Bertil Jonsson

Jonas Bergh

Affiliations

Soon will be listed here.

Abstract

Between January 2001 and January 2012, 48 new medicinal products for cancer treatment were licensed within the EU, and 77 new indications were granted for products already licensed. In some cases, a major improvement to existing therapies was achieved, for example, trastuzumab in breast cancer. In other cases, new fields for effective drug therapy opened up, such as in chronic myeloid leukemia, and renal-cell carcinoma. In most cases, however, the benefit-risk balance was considered to be only borderline favorable. Based on our assessment of advice procedures for marketing authorization, 'need for speed' seems to be the guiding principle in anticancer drug development. Although, for drugs that make a difference, early licensure is of obvious importance to patients, this is less evident in the case of borderline drugs. Without proper incentives and with hurdles inside and outside companies, a change in drug development cannot be expected; drugs improving benefit-risk modestly over available therapies will be brought forward towards licensure. In this Perspectives article, we discuss some hurdles to biomarker-driven drug development and provide some suggestions to overcome them.

Citing Articles

Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.

Cho I, Han E Int J Environ Res Public Health. 2022; 19(5).

PMID: 35270550 PMC: 8910054. DOI: 10.3390/ijerph19052857.

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.

Pontes C, Fontanet J, Vives R, Sancho A, Gomez-Valent M, Rios J Orphanet J Rare Dis. 2018; 13(1):206.

PMID: 30442155 PMC: 6238348. DOI: 10.1186/s13023-018-0926-z.

An appraisal of drug development timelines in the Era of precision oncology.

Jardim D, Schwaederle M, Hong D, Kurzrock R Oncotarget. 2016; 7(33):53037-53046.

PMID: 27419632 PMC: 5288167. DOI: 10.18632/oncotarget.10588.

Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.

Foukakis T, Lovrot J, Sandqvist P, Xie H, Lindstrom L, Giorgetti C Mol Oncol. 2015; 9(7):1384-91.

PMID: 25888067 PMC: 5528815. DOI: 10.1016/j.molonc.2015.03.011.

Bacterial proteins and peptides in cancer therapy: today and tomorrow.

Chakrabarty A, Bernardes N, Fialho A Bioengineered. 2014; 5(4):234-42.

PMID: 24875003 PMC: 4140868. DOI: 10.4161/bioe.29266.

References

Gao B, Klumpen H, Gurney H . Dose calculation of anticancer drugs. Expert Opin Drug Metab Toxicol. 2008; 4(10):1307-19. DOI: 10.1517/17425255.4.10.1307. View

Reichert J, Valge-Archer V . Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007; 6(5):349-56. DOI: 10.1038/nrd2241. View

Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G . Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol. 2009; 20(9):1499-1504. PMC: 2731014. DOI: 10.1093/annonc/mdp028. View

Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A . Targeted therapies: how personal should we go?. Nat Rev Clin Oncol. 2011; 9(2):87-97. DOI: 10.1038/nrclinonc.2011.164. View

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K . Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008; 26(26):4244-52. DOI: 10.1200/JCO.2007.15.0185. View

Goss G, Ferry D, Wierzbicki R, Laurie S, Thompson J, Biesma B . Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol. 2009; 27(13):2253-60. PMC: 4886538. DOI: 10.1200/JCO.2008.18.4408. View

Thompson A, Jordan L, Quinlan P, Anderson E, Skene A, Dewar J . Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010; 12(6):R92. PMC: 3046433. DOI: 10.1186/bcr2771. View

Arteaga C, Sliwkowski M, Osborne C, Perez E, Puglisi F, Gianni L . Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011; 9(1):16-32. DOI: 10.1038/nrclinonc.2011.177. View

Hait W . Anticancer drug development: the grand challenges. Nat Rev Drug Discov. 2010; 9(4):253-4. DOI: 10.1038/nrd3144. View

10.

Broich K . Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol. 2009; 19(5):305-8. DOI: 10.1016/j.euroneuro.2009.01.012. View

11.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Floriani I, Garattini S, Torri V . Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Ann Oncol. 2010; 21(7):1391-1393. DOI: 10.1093/annonc/mdq266. View

14.

Bergh J . Quo vadis with targeted drugs in the 21st century?. J Clin Oncol. 2008; 27(1):2-5. DOI: 10.1200/JCO.2008.18.8342. View

15.

Quintas-Cardama A, Kantarjian H, Cortes J . Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009; 6(9):535-43. DOI: 10.1038/nrclinonc.2009.112. View

16.

Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View

17.

Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D . The cost of drug development: a systematic review. Health Policy. 2011; 100(1):4-17. DOI: 10.1016/j.healthpol.2010.12.002. View

18.

Druker B, Lydon N . Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000; 105(1):3-7. PMC: 382593. DOI: 10.1172/JCI9083. View

19.

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

20.

Lievre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. DOI: 10.1158/0008-5472.CAN-06-0191. View